HC Wainwright Weighs in on Kura Oncology Q1 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Kura Oncology in a note issued to investors on Thursday, February 27th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.80) per share for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. HC Wainwright also issued estimates for Kura Oncology’s Q3 2025 earnings at ($0.76) EPS and Q4 2025 earnings at ($0.78) EPS.

KURA has been the topic of a number of other reports. TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. BTIG Research downgraded shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Scotiabank decreased their price target on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. Jefferies Financial Group cut their price objective on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. Finally, StockNews.com upgraded Kura Oncology from a “sell” rating to a “hold” rating in a report on Thursday. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.13.

Kura Oncology Price Performance

KURA stock opened at $7.65 on Friday. The business’s fifty day moving average price is $8.19 and its 200 day moving average price is $13.92. Kura Oncology has a 12-month low of $6.98 and a 12-month high of $24.17. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $594.89 million, a PE ratio of -3.24 and a beta of 0.78.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million.

Insider Transactions at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the sale, the insider now owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of KURA. RA Capital Management L.P. acquired a new stake in shares of Kura Oncology during the fourth quarter worth about $38,769,000. Millennium Management LLC increased its position in Kura Oncology by 180.1% during the fourth quarter. Millennium Management LLC now owns 2,367,148 shares of the company’s stock worth $20,618,000 after buying an additional 1,521,954 shares during the period. Jacobs Levy Equity Management Inc. purchased a new stake in Kura Oncology in the fourth quarter valued at approximately $8,518,000. Marshall Wace LLP acquired a new stake in shares of Kura Oncology in the fourth quarter valued at approximately $8,265,000. Finally, D. E. Shaw & Co. Inc. grew its position in shares of Kura Oncology by 172.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,151,195 shares of the company’s stock worth $10,027,000 after acquiring an additional 727,987 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.